-
-
-
-
-
-
-
TD Cowen highlights this stock as a best SMID-cap idea with multiple 2026 catalysts
-
-
-
-
-
-
-
Krystal Biotech (KRYS) PT Raised to $327 at Goldman Sachs
-
-
-
-
-
-
-
BofA top picks in biotech as sector heading for recovery in 2026
-
-
-
-
-
-
-
Krystal Biotech (KRYS) PT Lowered to $216 at Chardan Capital Markets
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Krystal Biotech (KRYS)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Krystal Biotech (KRYS)
-
-
-
-
-
-
-
Jefferies Starts Krystal Biotech (KRYS) at Buy
-
459,828 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

